BioCentury | Feb 14, 2020
Targets & Mechanisms

Entrepreneur watch: Iwasaki targets the lymphatic system to clear brain tumors

Rising serial entrepreneur Akiko Iwasaki aims to bring antitumor immunity to the brain by opening the brain’s lymphatics, a recently discovered system of vessels just starting to find translational uses. In 2015, a Nature paper...
BioCentury | Dec 27, 2019
Clinical News

Spring Bank’s HBV therapy on hold after signs of liver damage

Spring Bank’s revelation of liver toxicity in chronic HBV patients treated with inarigivir soproxil in a Phase IIb trial sent the company’s shares down 67% Thursday; however, the readout doesn’t necessarily mean that immuno-oncology therapies...
BioCentury | Dec 6, 2019
Targets & Mechanisms

Emerging immuno-oncology mechanisms at ASH 2019

Researchers are finding new ways to monitor the immune system in hematologic diseases that could have implications for optimizing immuno-oncology therapies, according to BioCentury’s analysis of emerging targets at ASH 2019. In abstracts released ahead...
BioCentury | Jul 26, 2019
Preclinical News

July 26 preclinical Quick Takes: Ribon's new mechanism for PARP inhibitors, a microbiome-ALS link and more

Ribon co-founder reports new mechanism for PARP inhibitors An University of Texas Southwestern team led by Ribon Therapeutics Inc. (Lexington, Mass.) co-founder W. Lee Kraus reported that PARP inhibitors block ribosome production, and therefore tumor...
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
BioCentury | Feb 20, 2019
Distillery Therapeutics

Infectious disease

INDICATION: West Nile virus In vitro and cell culture studies identified a benzenesulfonamide-based DDX3X inhibitor that could help treat West Nile viral infection. Chemical synthesis and in vitro screening of analogs of a previously reported...
BioCentury | Nov 2, 2018
Targets & Mechanisms

FDA’s pediatric target picks

FDA is looking ahead of industry in its guideline on targets for pediatric oncology, which includes more than 50 not yet in company pipelines in a list of over 220 the agency has its eye...
BioCentury | Oct 6, 2018
Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
BioCentury | Aug 10, 2018
Clinical News

Spring Bank details peak HBV DNA and HBV RNA reductions for 100 mg dose of inarigivir

Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH) reported data from 20 patients in the third cohort of Part A of Phase II ACHIEVE trial to treat chronic HBV infection showing that 100 mg inarigivir soproxil led to...
BioCentury | Apr 3, 2018
Targets & Mechanisms

Sensor sensibility

Zhijian “James” Chen’s discovery of the DNA sensor cGAS revealed the missing link between cytosolic DNA and innate immune activation, paving the way for immunotherapies targeting the cGAS-STING pathway. The lowest-hanging fruit has been in...
Items per page:
1 - 10 of 77